Logo

GeneGo Licenses MetaCore to Velcura for Three Years

Nov 10, 2005

NEW YORK, Nov. 10 (GenomeWeb News) - GeneGo has has licensed its pathway database and data mining software to Velcura Therapeutics for three years, the companies said today.

 

Velcura plans to use the MetaCore product for gene expression analysis and proteomic analysis in bone-related disease research, the companies said.

 

GeneGo and Velcura did not disclose financial details of the agreement.

Breaking News
The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.